Curated News
By: NewsRamp Editorial Staff
October 15, 2026

Tonix to Present TNX-801 Mpox Vaccine Data at World Vaccine Congress Europe

Original Source

TLDR

  • Tonix Pharmaceuticals will present TNX-801, a horsepox-based vaccine platform, at the World Vaccine Congress Europe, positioning it as a key player in mpox defense.
  • TNX-801 is a live, attenuated, minimally replicative horsepox virus-based vaccine platform developed to protect against mpox and other infectious diseases.
  • Tonix's TNX-801 vaccine platform aims to protect against mpox and other infectious diseases, potentially improving global health and saving lives.
  • Tonix Pharmaceuticals will lead a working group on vectored vaccine platforms and present on TNX-801 at the World Vaccine Congress Europe in Amsterdam in 2026.

Impact - Why it Matters

Tonix’s participation at the World Vaccine Congress Europe underscores the company’s commitment to advancing innovative vaccine platforms for infectious diseases like mpox, which remains a global health concern. The TNX-801 platform, based on horsepox virus, represents a novel approach that could offer advantages over existing vaccines. Positive data could position Tonix as a key player in the vaccine market, potentially attracting investors and partners. Moreover, the company’s diverse pipeline, including treatments for fibromyalgia, depression, and rare diseases, highlights its broader impact on patient care. For investors, this event could be a catalyst for TNXP stock, while for the public, it signals progress toward new tools to combat infectious diseases.

Summary

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, has announced that it will deliver an oral presentation on its investigational TNX-801 vaccine platform and lead a working group session at the World Vaccine Congress Europe, taking place October 19-21, 2026, in Amsterdam, Netherlands. The presentation, scheduled for October 21 at 1:15 p.m. CEST, will focus on the safety and efficacy of TNX-801, a live, attenuated, minimally replicative horsepox virus-based vaccine platform being developed to protect against mpox and other infectious diseases. Tonix will also lead a working group session titled “Vectored Vaccine Platforms: From Design to Improving Efficacy” on October 20 at 11:30 a.m. CEST. For full details, readers can view the full press release at https://ibn.fm/BHVjU.

Tonix Pharmaceuticals is focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Its recently approved flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years. The company’s CNS commercial infrastructure supports its marketed products, including acute migraine products Zembrace SymTouch and Tosymra. Tonix is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Additionally, its CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. It is important to note that Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Investors and stakeholders can find the latest news and updates relating to TNXP in the company’s newsroom at https://ibn.fm/TNXP. The announcement was distributed through BioMedWire, a specialized communications platform focusing on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.

Source Statement

This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix to Present TNX-801 Mpox Vaccine Data at World Vaccine Congress Europe

Blockchain registration record for this content